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Abstract
The molecular bases of Alzheimer’s disease (AD) remain unclear. We used a lipidomic approach to identify lipid
abnormalities in the brains of subjects with AD (N=37) compared to age-matched controls (N=17). The analyses revealed
statistically detectable elevations in levels of non-esterified monounsaturated fatty acids (MUFAs) and mead acid (20:3n-9) in
mid-frontal cortex, temporal cortex and hippocampus of AD patients. Further studies showed that brain mRNAs encoding
for isoforms of the rate-limiting enzyme in MUFAs biosynthesis, stearoyl-CoA desaturase (SCD-1, SCD-5a and SCD-5b), were
elevated in subjects with AD. The monounsaturated/saturated fatty acid ratio (‘desaturation index’) – displayed a strong
negative correlation with measures of cognition: the Mini Mental State Examination test (r=20.80; P=0.0001) and the
Boston Naming test (r=20.57; P=0.0071). Our results reveal a previously unrecognized role for the lipogenic enzyme SCD
in AD.
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Introduction
Alzheimer’s disease (AD), the most common cause of adult
dementia, is characterized by progressive memory impairment,
deterioration of language, and visuospatial deficits [1]. Age is the
most important factor that predisposes persons to the non-familial
(‘sporadic’) form of this disease, which affects an estimated 35
million of elderly people worldwide [2]. It is still unknown how
aging interacts with other risk factors of AD – such as abnormal
accumulation of Ab peptides and hyperphosphorylated tau protein
in the brain [1]. Nevertheless, it is clear that the development of
AD can be influenced by a variety of age-related conditions that
are closely associated with systemic dysfunctions in metabolism –
including obesity, diabetes and atherosclerosis [3,4,5]. In partic-
ular, there is evidence suggesting a link between alterations in lipid
metabolism and AD. For example, the inheritance of certain
isoforms of the lipid-carrier protein, apolipoprotein E (ApoE), is
known to increase the risk of AD [6]. Moreover, post mortem
analyses of frozen brain samples have documented the existence of
multiple lipid abnormalities in AD patients, including changes in
ceramides, n-3 polyunsaturated fatty acids (PUFA) and PUFA-
derived signaling lipids [7,8,9,10,11].
In the present study, we utilized a lipidomic approach to identify
novel lipid alterations in brain tissue of subjects with AD. We used
liquid chromatography/mass spectrometry (LC/MS) to survey
frozen brain samples from clinically characterized AD patients and
age-matched controls. We found that the levels of nervonic acid
(24:1n-9) and other monounsaturated fatty acids (MUFAs) are
markedly increased in brain tissue of AD patients. This increase
was strongly associated with cognitive dysfunction and was
accompanied by enhanced transcription in brain tissue of the
rate-limiting enzyme in MUFAs biosynthesis, stearoyl-CoA
desaturase (SCD) [12,13,14,15,16,17,18].
Results
To identify novel molecular alterations in AD, we compared
lipid profiles of mid-frontal cortex samples from 17 control subjects
and 37 AD patients. The demographic and neuropathological
characteristics of the subjects with AD and the control subjects
used in this study are shown in Table 1. The groups were closely
matched for age and post mortem interval. We extracted tissue
lipids with organic solvents and analyzed the extracts by LC/MS
using an untargeted approach in which we first acquired data
relative to all detectable molecular species of m/z 250–500, and
then compared data sets obtained from AD and control subjects
using algorithms for noise suppression and subtraction of similar
molecular features [19]. A representative example of these initial
analyses is reported in Fig. 1A. The results suggested that a
molecular species of m/z 365.3 and retention time 18 min was
elevated in AD patients, compared to controls (Fig. 1A, arrow).
Further LC/MS
n characterization and comparison with an
authentic standard identified this molecule as nervonic acid
(Fig. 1B), a long-chain MUFA (24:1n-9) that is particularly
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sures confirmed that nervonic acid levels were significantly
elevated in the mid-frontal and temporal cortices of subjects with
AD, relative to control subjects (Fig. 1C,D). No such difference
was observed in cerebellum (Fig. 1E).
The biosynthesis of nervonic acid starts with the desaturation of
stearic acid (18:0) into oleic acid (18:1n-9) catalyzed by SCD
activity and proceeds through a series of elongation steps that lead
to the production of nervonic and ximenic acid (26:1n-9) (Fig. 2A).
Collateral pathways initiated by SCD convert palmitic acid (16:0)
into palmitoleic acid (16:1n-7) and stearic acid (18:0) into mead
acid (20:3n-9) (Fig. 2A). To determine whether nervonic acid
biosynthesis is up-regulated in AD, we quantified these metabolic
intermediates and found their levels to be increased in mid-frontal
cortex, temporal cortex, and hippocampus of AD patients
compared to controls (Tables 2, 3, 4). By contrast, no changes in
MUFA content were found in cerebellum (Table 5). Moreover,
there were no differences in the levels of saturated fatty acids
(SFAs) between subjects with AD and control subjects (Table 2, 3,
4, 5). The ratio between monounsaturated fatty acids (16:1n-7,
18:1n-9) and their saturated precursors (16:0, 18:0) (‘desaturation
index’) – was significantly higher in mid-frontal cortex, temporal
cortex and hippocampus of subjects with AD compared to control
subjects (Table 2, 3, 4). Confirming previous work [20], we
recently reported that levels of docosahexaenoic acid (DHA) are
decreased in the brains of AD subjects compared to controls [9].
Here, we found a marginal, albeit statistically significant
correlation between the desaturation index (16:1/16:0) and
DHA levels (P,0.049; r=20.27) in the mid-frontal cortex of
subjects with AD relative to controls.
These results identify a previously unrecognized increase in
MUFAs levels in the brains of AD patients, suggesting that brain
SCD expression might also be elevated in these subjects. This
possibility was confirmed by quantitative RT-PCR analyses, which
showed that levels of mRNA encoding for SCD-1, SCD-5a and
SCD-5b – three SCD isoforms present in the human brain [13,21]
– were elevated in hippocampus of AD patients (Fig. 2B–D). In
mid-frontal cortex, only the mRNA encoding for SCD-5b was
found to be increased (Fig. 2E).
To determine whether the increase in free nervonic acid is due
to an up-regulation of MUFA biosynthesis or MUFA release from
sphingolipids, we measured the levels of nervonic acid-containing
molecular species in the mid-frontal cortex of subjects with AD
compared to control subjects. No changes were observed in the
levels of selected ceramide, sphingomyelin, and cerebroside species
(Fig. 3). These findings support the conclusion that AD might be
associated with an up-regulation of MUFA biosynthesis, rather
than a non-specific alteration in sphingolipid content. We cannot
exclude, however, the possibility that the effects observed here
might be due, at least in part, to changes in the gray/white matter
ratio between controls and subjects with AD.
Next, to explore the clinical significance of our findings, we
searched for statistical correlations between MUFA levels and
measures of cognitive function. We found that the desaturation
index (16:1/16:0) in mid-frontal cortex displayed a strong negative
correlation with cognitive scores from two standard neuropsycho-
metric tests: the Mini-Mental Status Examination test (which
assesses global cognition; r=20.80; P=0.0001) and the Boston
Naming test (which assesses language facility; r=20.57;
P=0.0071) (Fig. 4). These findings point to the existence of a
functional link between heightened MUFA levels in the brain and
deterioration of mental functions in subjects with AD. The results
do not establish, however, whether this link represents causation,
and do not elucidate the molecular mechanisms responsible for
increased MUFA levels in AD.
SCD is a key lipogenic enzyme. Indeed, by converting SFAs
into MUFAs, SCD provides preferred substrates for the acyl-
CoA:cholesterol acyl transferase (ACAT), an enzyme that
catalyzes the conversion of cholesterol into cholesteryl esters.
ACAT inhibitors are potent hypolipidemic and antiatherosclerotic
drugs, which might also reduce AD pathology [22,23,24]. To
determine whether the observed increase in MUFAs availability
affected cholesterol homeostasis in AD, we measured the levels of
both cholesteryl esters and cholesterol by LC/MS. We found that
the levels of cholesteryl esters and the cholesteryl esters/cholesterol
ratio were increased in mid-frontal cortex of subjects with AD
compared to control subjects (Fig. 5). These results highlight a
potential role played by SCD in the regulation of cholesterol
homeostasis in AD brain. In contrast, no changes were observed
for total triglycerides (TG) in mid-frontal cortex of subjects with
AD compared to control subjects [25,26].
Discussion
Our results identify a previously unrecognized alteration in the
neural lipidome, which appears to be associated with AD. Using an
untargeted lipidomic strategy, we found that the levels of nervonic
acid and other MUFAs produced by SCD are markedly elevated in
frozen brain samples from AD patients, compared to age-matched
control subjects, and that these changes strongly correlate with
cognitive impairment. We further found that the transcription of
three SCD isoforms present in the human brain – SCD-1, SCD-5a
and SCD-5b – is heightened in AD. These findings reveal an
unexpected role for brain MUFAs and SCD in AD.
Although the functional consequences of elevated brain MUFA
levels are unclear at present, peripheral SCD is recognized to be a
critical control point in the development of metabolic diseases.
Elevated levels of SCD activity and desaturation index appear to
be associated with key aspects of the metabolic syndrome – insulin
resistance, abdominal adiposity and hyperlipidemia – and have
been proposed as biological markers for this condition [13,
14,15,17,18,26]. Furthermore, animal studies have shown that
SCD-derived palmitoleate (16:1n-7) participates as a blood-borne
Table 1. Demographic and neuropathological features of the
subjects used in this study.
AD patients Control subjects
Total number 37 (all Caucasian) 17 (all Caucasian)
Sex (male/female) 20/17 10/7
Age (years)
Age range (years)
80.467.3
63–95
80.468.5
64–96
Post mortem interval (hours) 4.261.7 4.461.5
Plaque score (CERAD)
Range: 0–3 (Stage 0-C)
2.7660.10 0.3360.21
Tangle score (Braak and Braak)
Range: 0–6 (Stage 0-VI)
5.6760.11 2.3360.21
MMSE score 11.467.2 28.361.8
Body weight (lb) 145.3634.6 (N=31) 171.261.4 (N=2)
Brain hemisphere (left/right) 19/18 8/7; NA (N=2)
Freezer storage duration (years) 5.662.4 7.663.8
Plus-minus values are means 6 SD.
Abbreviations: CERAD, Consortium to Establish a Registry for AD; MMSE, Mini-
Mental Status Examination; NA, not available.
doi:10.1371/journal.pone.0024777.t001
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resistance [27]. Because of these discoveries, SCD has recently
emerged as a possible target for the treatment of diabetes,
hyperlipidemia and obesity [28,29,30].
Two distinct SCD isoforms (SCD-1 and SCD-5) are expressed
in human tissues, but little is known about the substrate specificity
and functional roles of these variants. Human SCD-1 shares about
85% amino-acid identity with the four known rodent isoforms and
is highly expressed in brain, liver and adipose tissue [31]. By
contrast, human SCD-5 isoforms have limited homology with
rodent SCD and are predominantly expressed in brain and
pancreas [21,32]. Previously studies have documented a progressive
increase in MUFA levels and SCD-1 expression in human frontal
cortex during normal aging and in patients with bipolar disorder
[33]. Such an increase was paralleled by lowered levels of the n-3
polyunsaturated fatty acid, DHA [34], which is consistent with the
ability of polyunsaturated fatty acids (PUFAs) to negatively regulate
SCD expression [35]. In agreement with those data, previous work
from our laboratory and others has reported that free DHA levels
are markedly decreased in the brain of subjects with AD [9,20].
Notably, the up-regulation of MUFA levels was accompanied by
an increase in mead acid (20:3n-9) (Tables 2, 3, 4), which is the only
non-essential PUFA that can be synthesized through a de novo
pathway, in which SCD appear to be the rate-limiting enzyme
(Fig. 2A). In conditions of DHA deficit, mead acid could contribute
to maintain a homeostasis in the unsaturation level of the cellular
Figure 1. Untargeted lipidomic analyses. Representative mirror-display images and differential LC/MS analysis of lipids from a subject with AD
and a control subject. The component detected as being qualitatively different between the two samples (Panel A, arrow), was subsequently
identified as nervonic acid, using LC/MS
2 (Panel B). Quantitative measures of nervonic acid in mid-frontal cortex (Panel C), temporal cortex (Panel D)
and cerebellum (Panel E) from control subjects (open squares) and AD patients (closed circles). Two-tailed Welch’s t-test.
doi:10.1371/journal.pone.0024777.g001
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e24777Figure 2. Overview of MUFAs biosynthesis and levels of SCD mRNA in the brain of subjects with AD and control subjects. Palmitic
acid (16:0) is transformed into palmitoleic acid (16:1n-7) by the action of SCD (Panel A). Palmitic acid can also be transformed into stearic acid (18:0)
by elongase activity (such as those encoded by ELOVL genes) and subsequently into oleic acid (18:1) by SCD activity (Panel A). Oleic acid can be then
converted into longer chain fatty acids by sequential action of elongases and D
5 and D
6 desaturases (encoded by the FASD1 and FASD2 genes,
respectively, Panel A). Levels of mRNA for SCD-1 (Panel B), SCD-5a (Panel C) and SCD-5b (Panel D) in hippocampus and SCD-5b (Panel E) in mid-frontal
cortex from control subjects (N=17, open squares) and AD patients (N=28, closed circles). Two-tailed Welch’s t-test.
doi:10.1371/journal.pone.0024777.g002
Table 2. Levels of MUFAs and mead acid (nmol/g) in mid-frontal cortex of control subjects and subjects with AD.
Fatty acid Control subjects Subjects with AD Adjusted Difference P-value
Mean ± SD; N=17 Mean ± SD; N=37 (95% CI)
16:1 17.5161.22 21.6760.89 24.16 (27.25, 21.07 ) 0.010
18:1 171.7067.54 193.3367.5 221.64 (243.12, 20.15 ) 0.048
20:1 10.1160.58 12.9360.95 22.82 (25.11, 20.52 ) 0.017
22:1 0.8560.10 1.8160.25 20.95 (21.48, 20.42 ) 0.0007
24:1 1.8960.14 4.1660.50 22.26 (23.29, 21.23 ) ,0.0001
26:1 1.5060.17 3.5760.40 22.08 (22.95, 21.21 ) ,0.0001
MUFAs 203.669.30 237.569.90 233.91 (261.30, 26.51 ) 0.016
20:3 n-9 4.1660.33 7.3660.81 23.20 (24.96, 21.43 ) 0.0007
16:0 156.2065.87 162.0064.98 25.84 (221.54, 9.85) 0.45
18:0 252.4068.67 249.2068.62 3.22 (221.54, 227.99) 0.79
20:0 1.5560.15 1.8860.11 20.33 (20.72, 0.047) 0.083
22:0 0.7160.10 0.9260.065 20.21 (20.46, 20.043) 0.10
SFAs 409.9614.90 405.5614.27 4.39 (237.56, 46.34) 0.83
16:1/16:0 0.1160.0040 0.1360.0040 20.024 ( 20.037, 20.011 ) 0.0008
18:1/18:0 0.6860.020 0.7860.022 20.095 (20.15, 20.035 ) 0.0027
MUFAs/SFAs 0.5060.015 0.5960.021 20.095 (20.15, 20.042 ) 0.0007
Abbreviations: CI, confidence interval. P values for differences between means were computed by linear regression analysis for each fatty acid after adjustment for age,
gender, and post mortem interval.
doi:10.1371/journal.pone.0024777.t002
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decreased DHA levels, an elevation in the levels of mead acid might
serve as an additional biological marker for AD.
As with all observational studies, there is the possibility that
unmeasured factors may explain our results, even though we chose
a priori to adjust for the three most likely confounders – age,
gender and post mortem interval. For example, medication history
was only partly available for our subject groups and additional
work is needed, therefore, to evaluate its potential impact.
Furthermore, although we paid particular attention in using
exclusively gray matter that was appropriately dissected by an
experienced neuropathologist, we cannot exclude the possibility
Table 3. Levels of MUFAs and mead acid (nmol/g) in temporal cortex of control subjects and subjects with AD.
Fatty acid Control subjects Subjects with AD Adjusted Difference P-value
Mean ± SD; N=17 Mean ± SD; N=37 (95% CI)
16:1 14.1861.07 14.6260.71 20.43 (23.10, 2.23) 0.74
18:1 192.5610.35 190.268.04 2.34 (224.56, 29.23) 0.86
20:1 9.6460.81 11.0961.15 21.45 (24.30, 1.40) 0.31
22:1 2.1160.22 2.5160.31 20.40 (21.17, 0.38) 0.31
24:1 2.0060.30 3.5960.55 21.59 (22.87, 20.32) 0.015
26:1 1.1160.30 2.2660.48 21.14 (22.29, 0.0012) 0.050
MUFAs 221.6612.19 224.7610.43 23.09 (235.85, 29.67) 0.85
20:3 n-9 4.0760.42 6.2460.70 22.18 (23.81, 20.54) 0.010
16:0 164.267.80 153.265.32 10.93 (28.60, 30.46) 0.26
18:0 279.3616.66 249.269.37 30.08 (29.80, 69.95) 0.13
20:0 2.3160.24 2.2060.14 0.12 (20.46, 0.70) 0.68
22:0 2.0360.82 1.2160.17 0.82 (20.99, 2.64) 0.35
SFAs 447.8624.15 405.9614.22 41.94 (216.53, 100.4) 0.15
16:1/16:0 0.08360.0040 0.09660.0033 20.012 (20.023, 20.0016) 0.025
18:1/18:0 0.7060.024 0.7860.028 20.079 (20.15, 0.0058) 0.035
MUFAs/SFAs 0.5060.014 0.5660.020 20.061 (20.11, 20.013) 0.014
Abbreviations: CI, confidence interval. P values for differences between means were computed by linear regression analysis for each fatty acid after adjustment for age,
gender, and post mortem interval.
doi:10.1371/journal.pone.0024777.t003
Table 4. Levels of MUFAs and mead acid (nmol/g) in hippocampus of control subjects and subjects with AD.
Fatty acid Control subjects Subjects with AD Adjusted Difference P-value
Mean ± SD; N=17 Mean ± SD; N=37 (95% CI)
16:1 8.7060.68 19.8061.04 211.10 (213.61, 28.58 ) ,0.0001
18:1 141.3613.27 180.7610.95 239.39 (274.29, 24.48) 0.028
20:1 5.8260.43 8.216065 22.40 (23.99, 20.80) 0.0042
22:1 2.2760.33 2.7560.36 20.47 (21.46, 0.51) 0.34
24:1 4.2760.93 3.4060.44 0.86 (21.26, 2.99) 0.41
26:1 6.3561.34 4.8260.72 1.54 (21.67, 4.74) 0.33
MUFAs 167.7615.73 219.6613.35 251.99 (293.85, 210.12) 0.029
20:3 n-9 15.3462.11 22.9862.41 27.63 (214.10, 1.17) 0.022
16:0 154.80610.50 171.5067.44 216.67 (242.67, 9.57) 0.20
18:0 262.80621.19 241.31611.16 21.53 (228.80, 70.85) 0.38
20:0 5.7860.68 4.0360.21 1.75 (20.28, 3.23) 0.022
22:0 1.9960.33 1.1960.074 0.80 ( 0.092, 1.50) 0.029
SFAs 425.4632.10 418.01618.46 7.41 (268.72, 83.55) 0.84
16:1/16:0 0.05860.0044 0.1260.0049 20.059 (20.072, 20.046) ,0.0001
18:1/18:0 0.5560.047 0.7560.030 20.20 (20.31, 20.085) 0.0013
MUFAs/SFAs 0.4160.0038 0.5260.0020 20.11 (20.20, 20.032) 0.0086
Abbreviations: CI, confidence interval. P-values for differences between means were computed by linear regression analysis for each fatty acid after adjustment for age,
gender, and post mortem interval.
doi:10.1371/journal.pone.0024777.t004
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in MUFA levels observed in AD brains. Despite these limitations,
our study does point to a previously unrecognized connection
between cognitive impairment in AD and up-regulation of the
lipogenic enzyme SCD. Future investigations need to explore the
molecular basis for this putative association as well as its possible
implications in the diagnosis and treatment of AD.
Materials and Methods
Human brain tissue procurement
We used frozen brain samples from a total of 17 non-demented
control subjects and 37 pathologically confirmed subjects with AD
(males/females: control subjects, 10/7; subjects with AD, 20/17),
provided by the Institute for Brain Aging and the Dementia and
Alzheimer’s Disease Research Center at the University of
California, Irvine. Average sample weight was 36.861.0 mg,
mean6SEM (N=54). Four brain areas rich in gray matter were
selected for analysis: mid-frontal cortex (Brodmann area 9),
temporal cortex (Brodmann area 20), hippocampus (Brodmann
area 34) and cerebellum. Subjects were matched for age (in years:
control subjects, 80.468.5; subjects with AD, 80.467.3) and post
mortem interval (in hours: control subjects, 4.461.5; subjects with
AD, 4.261.7). AD cases met the National Institute on Aging-
Reagan Institute criteria for intermediate or high likelihood of AD.
Psychometric tests were used for correlative analyses when
Table 5. Levels of MUFAs and mead acid (nmol/g) in cerebellum of control subjects and subjects with AD.
Fatty acid Control subjects Subjects with AD Adjusted Difference P-value
Mean ± SD; N=17 Mean ± SD; N=37 (95% CI)
16:1 16.4561.34 17.4260.60 20.97 (24.012, 2.07) 0.52
18:1 253.2618.90 230.366.84 22.83 (219.25, 64.90) 0.27
20:1 17.3361.82 15.4760.78 22.26 (22.26, 5.98) 0.36
22:1 2.7160.29 3.4060.65 20.68 (22.12, 0.76) 0.34
24:1 4.360.50 3.5660.34 0.71 (20.52, 1.94) 0.25
26:1 4.1660.55 4.3260.57 20.15 (21.757, 1.45) 0.85
MUFAs 290.2622.27 273.768.09 16.44 (232.99, 65.88) 0.50
20:3 n-9 6.1660.65 7.6060.43 21.43 (23.03, 0.16) 0.077
16:0 204.1618.36 198.367.87 5.85 (235.95, 47.65) 0.77
18:0 395.7626.25 367.4611.90 28.35 (231.78, 88.48) 0.34
20:0 3.8960.44 3.3360.29 0.56 (20.53, 1.64) 0.30
22:0 1.7160.21 1.5760.16 0.14 (20.42, 0.69) 0.62
SFAs 605.5643.45 570.6617.63 34.89 (263.62, 133.4) 0.47
16:1/16:0 0.08060.0047 0.09260.0025 20.011 (20.022, 20.00022) 0.046
18:1/18:0 0.6260.029 0.6360.014 20.010 (20.077, 0.057) 0.76
MUFAs/SFAs 0.4860.021 0.4860.0092 20.0019 (20.049, 0.046) 0.94
Abbreviations: CI, confidence interval. P values for differences between means were computed by linear regression analysis for each fatty acid after adjustment for age,
gender, and post mortem interval.
doi:10.1371/journal.pone.0024777.t005
Figure 3. Levels of nervonic acid-containing lipids in the brain of subjects with AD and control subjects. Levels of ceramide d18:1/24:1
(Panel A), sphingomyelin d18:1/24:1 (Panel B), hexosylceramide d18:1/24:1 (Panel C) in mid-frontal cortex from control subjects (N=17, open squares)
and AD patients (N=37, closed circles). Two-tailed Welch’s t-test.
doi:10.1371/journal.pone.0024777.g003
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control subjects and 11.066.2 months before death for subjects
with AD. All subjects and their caregivers (when appropriate)
provided informed written consent for both the clinical examina-
tion as well as for brain donation at the University of California
Irvine. The protocols and informed consent have been approved
by the University of California Irvine Institutional Biosafety
Committee.
Lipid extractions
Lipid extractions were conducted as described [36]. Briefly,
frozen brain samples were rapidly weighed and homogenized in
ice-cold methanol containing appropriate internal standards (listed
below). Lipids were extracted by adding chloroform and water (2/
1, vol/vol) and fractionated through open-bed silica gel columns
by progressive elution with chloroform/methanol mixtures.
Fractions eluted from the columns were dried under nitrogen,
reconstituted in chloroform/methanol (1:4, vol/vol; 0.1 ml) and
subjected to LC/MS.
Untargeted lipidomic analyses
Unbiased lipidome-wide analyses were conducted using an
Agilent 1100-LC system coupled to an ion-trap XCT mass
detector equipped with an electrospray ionization (ESI) interface
(Agilent Technologies, Inc., Palo Alto, CA). Lipid extracts were
separated on a XDB Eclipse C18 column (5064.6 mm i.d.,
1.8 mm, Zorbax, Agilent Technologies) and they were eluted with
a gradient of methanol in water (from 60% to 100% methanol in
20 min) at a flow rate of 1 ml/min. Column temperature was kept
at 30uC. Capillary voltage was set at 3 kV and fragmentor voltage
was 120 V. N2 was used as drying gas at a flow rate of 13 liters/
min and a temperature of 350uC. Nebulizer pressure was set at 60
PSI. Lipids were analyzed in full scan mode from 250 to 500 mass-
to-charge ratio (m/z) in both positive and negative ionization
mode. Data analyses, which consisted in application of algorithms
for noise and background reduction and differential comparative
analyses, were performed using MS Processor from Advanced
Chemistry Development, Inc. (Toronto, Canada). The COM-
PARELCMS input parameters were as follows: MCQ thresh-
Figure 4. Correlation between brain MUFA levels and cognitive function in subjects with AD and control subjects. Correlation
between desaturation index (16:1/16:0) in mid-frontal cortex and most recent neuropsychometric scores from control subjects (open squares) and
subjects with AD (closed circles). There were significant correlations between individual desaturation indices and available Mini-Mental State
Examination scores (Panel A) and Boston Naming Test scores (Panel B). Partial correlation analysis after adjustment for age, gender and post mortem
interval.
doi:10.1371/journal.pone.0024777.g004
Figure 5. Levels of cholesteryl esters and TG in the brain of subjects with AD and control subjects. Levels of total cholesteryl esters
(Panel A), cholesteryl esters to cholesterol ratio (Panel B) and total TGs (Panel C) in mid-frontal cortex from control subjects (N=17, open squares) and
AD patients (N=37, closed circles). Two-tailed Welch’s t-test.
doi:10.1371/journal.pone.0024777.g005
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Peak Width=20 scans; Delta Scan Level=3 scans; Ratio
Level=5; Additional Data Reduction=ON; Baseline Correc-
tion=OFF. The processing took approximately 120 seconds on a
Pentium IV 1.5 GHz computer.
Targeted lipidomic analyses
Lipid molecular species were quantified by normalizing the
individual molecular ion peak intensity with an internal standard
for each lipid class. A mixture of non-endogenous molecules was
used as internal standards and added before the extraction process
to allow lipid levels to be normalized for both extraction efficiency
and instrument response.
Fatty acids. Fatty acids were quantified with an Agilent 1100
liquid chromatograph coupled to a 1946D mass detector equipped
with an electrospray ionization interface (Agilent Technologies,
Palo Alto, CA). A reversed-phase XDB Eclipse C18 column
(5064.6 mm i.d., 1.8 mm, Zorbax, Agilent Technologies) was
eluted with a linear gradient from 90% to 100% of A in B for
2.5 min at a flow rate of 1.5 ml/min with column temperature at
40uC. Mobile phase A consisted of methanol containing 0.25%
acetic acid and 5 mM ammonium acetate; mobile phase B
consisted of water containing 0.25% acetic acid and 5 mM
ammonium acetate. Column temperature was kept at 40uC. Mass
detection was in the negative ionization mode, capillary voltage
was set at 24.0 kV and fragmentor voltage was 120 V. Nitrogen
was used as drying gas at a flow rate of 13 liters/min and a
temperature of 350uC. Nebulizer pressure was set at 60 pounds
per square inch. For quantification purposes, the deprotonated
pseudo-molecular ions [M-H]
2 of the fatty acids were monitored
in the selected ion-monitoring mode, using d8-arachidonic acid
(Cayman Chemical, Ann Arbor, MI) as internal standard (m/
z=311.3). Commercially available fatty acids (Nu-Chek Prep,
Elysian, MN, Cayman Chemical or Sigma-Aldrich, St Louis, MO)
were used as references.
Sphingolipids. Sphingolipid molecular species were
analyzed by tandem mass spectrometry, using an Agilent 1100
liquid chromatograph coupled to an electrospray ionization-ion-
trap XCT mass detector. Ceramides were separated on a
Poroshell 300 SB C18 column (2.1675 mm i.d., 5 mm; Agilent
Technologies) maintained at 30uC. A linear gradient of methanol
in water containing 5 mM ammonium acetate and 0.25% acetic
acid (from 80% to 100% of methanol in 3 min) was applied at a
flow rate of 1 ml/min. Detection was in the positive mode,
capillary voltage was 4.5 kV, skim1 240 V, and capillary exit
2151 V. N2 was used as drying gas at a flow rate of 12 L/min,
temperature of 350uC, and nebulizer pressure of 80 psi. Helium
was used as collision gas. Nervonic-acid containing ceramide was
identified by comparison of its LC retention time and MS
n
fragmentation pattern with that of an authentic standard (Avanti
Polar Lipids). Extracted ion chromatograms were used to quantify
ceramide d18:1/24:1 [M+H]
+ (m/z=648.6.630.8.264.3), using
ceramide d18:1/12:0 [M+H]
+ (m/z=482.5.464.5.264.3) as an
internal standard. Complex sphingolipids were separated using a
reversed-phase Poroshell 300SB C18 column (2.1675 mm i.d.,
5 mm, Agilent) and eluted with a linear gradient from 85% to
100% of mobile phase A in B in 5 min at a flow rate of 1.0 ml/
min with column temperature at 50uC. Mobile phase composition
was as described above. The capillary voltage was set at 24.0 kV
and skimmer voltage at 240 V. Nitrogen was utilized as drying
gas at a flow rate of 10 liters/min, temperature at 350uC and
nebulizer pressure at 60 pounds per square inch. Helium was the
collision gas and fragmentation amplitude was set at 1.2 V. Mass
detection was set in either positive or negative ionization mode
and was controlled by the Agilent/Bruker Daltonics software
version 5.2. Sphingolipids were identified using reference
standards (Avanti Polar Lipids) and quantified by multiple
reaction monitoring as follows: sphingomyelin d18:1/24:1 [M]
+
(m/z=813.8.754.8), hexosylceramide d18:1/24:1 [M-H]
2 (m/
z=808.8), using sphingomyelin d18:1/12:0 [M]
+ (m/
z=647.8.588.8) and glucosylceramide d18:1/12:0 [M-H]
2 (m/
z=642.8) as internal standards.
Cholesterol and triacylglycerols (TGs). We used an
Agilent 1100-LC system coupled to a MS detector Ion-Trap
XCT interfaced with atmospheric pressure chemical ionization
(Agilent Technologies). Lipids were separated on a Poroshell
300SB C18 column (2.1675 mm i.d., 5 mm, Agilent Technologies)
at 50uC. A linear gradient of methanol in water containing 5 mM
ammonium acetate and 0.25% acetic acid (from 85% to 100% of
methanol in 4 min) was applied at a flow rate of 1 ml/min. MS
detection was set in positive mode. Corona discharge needle
voltage set at 4 kV. Capillary voltage was 4.0 kV, skim1 40 V, and
capillary exit at 118 V. Nitrogen was used as drying gas at a flow
rate of 10 liters/min, temperature of 350uC, nebulizer pressure of
50 PSI and vaporization temperature at 400uC. Helium was used
as collision gas. Cholesterol and total cholesteryl esters were
detected at m/z 369.3 ([cholesterol+H-H2O]
+). Total TGs were
quantified by integrating the area of the total ion current (m/z
700–900) at a selected interval of retention time (from 4 to 5 min),
using TG 19:1/19:1/19:1 (m/z 944.8, Nu-Chek Prep) as an
internal standard.
Gene expression
Total RNA was extracted from 10–50 mg of frozen brain tissue
using TRIzol reagent (Invitrogen, Carlsbad, CA) and was purified
with the RNeasy mini kit (Qiagen, Valencia, CA). RNA quality
was assessed using an Agilent BioAnalyzer and by UV spectro-
photometry. First-strand complementary DNAs were synthesized
using SuperScript II RNaseH reverse transcriptase (Invitrogen).
Reverse transcription of total RNA (2 mg) was carried out using
oligo(dT)12–18 primers for 50 min at 42uC. mRNA levels were
measured by quantitative real-time polymerase chain reaction
(RT-PCR) with a Mx 3000P system (Stratagene, La Jolla, CA).
The following primers and fluorogenic probes were purchased
from Applied Biosystems (TaqMan Gene Expression Assays,
Foster City, CA): SCD-1, Hs01682761_m1; SCD-5 transcript variant
1 (SCD-5a, NCBI Refseq#NM_001037582), Hs01125695_m1;
SCD-5 transcript variant 2 (SCD-5b, NCBI Refseq#NM_024906),
Hs01125106_m1. RNA levels were normalized using glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) as standard.
Statistical analyses
Descriptive statistics are presented as means 6 SD. The
differences between unadjusted mean values were determined by
two-tailed Welch’s t-test. Associations between parameters were
tested by partial correlation analysis (Pearson’s). We used linear
regression to estimate the association between individual lipid
species and AD, adjusting for age, gender, and post mortem
interval. All confidence intervals correspond to a 95% confidence
level.
Acknowledgments
We thank Daniel Gillen and Nicole Berchtold for helpful discussions. The
contribution of Graham McGibbon from Advanced Chemistry Develop-
ment, Inc., Faizy Ahmed from Agilent Technologies, Inc., and Agilent
Technologies/University of California Irvine Analytical Discovery Facility,
Center for Drug Discovery is gratefully acknowledged.
Stearoyl-CoA Desaturase in Alzheimer’s Disease
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e24777Author Contributions
Conceived and designed the experiments: GA DP. Performed the
experiments: GA KMJ VV NVD SKM. Analyzed the data: GA KMJ
VV. Contributed reagents/materials/analysis tools: DHC EH CWC.
Wrote the paper: GA DP.
References
1. Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:
329–344.
2. Prince M, Jackson J (2009) World Alzheimer Report. In:, , International AsD,
editor. London.
3. Finch CE (2005) Developmental origins of aging in brain and blood vessels: an
overview. Neurobiol Aging 26: 281–291.
4. Launer LJ (2005) The epidemiologic study of dementia: a life-long quest?
Neurobiol Aging 26: 335–340.
5. Whalley L, Dick F, McNeill G (2006) A life-course approach to the aetiology of
late-onset dementias. Lancet Neurology 5: 87–96.
6. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-
Vance MA, et al. (1993) Association of apolipoprotein E allele epsilon 4 with
late-onset familial and sporadic Alzheimer’s disease. Neurology 43: 1467–1472.
7. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, et al. (2004)
Involvement of oxidative stress-induced abnormalities in ceramide and
cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad
Sci U S A 101: 2070–2075.
8. Lukiw WJ, Pappolla M, Pelaez RP, Bazan NG (2005) Alzheimer’s disease–a
dysfunction in cholesterol and lipid metabolism. Cell Mol Neurobiol 25:
475–483.
9. Astarita G, Jung K, Berchtold N, Nguyen L, Gillen D, et al. (2010) Deficient
liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment
in Alzheimer’s disease. PLoS One 5: e12538.
10. Sanchez-Mejia R, Newman J, Toh S, Yu G, Zhou Y, et al. (2008) Phospholipase
A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer’s
disease. Nat Neurosci 11: 1311–1318.
11. Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, et al. (2005)
Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and
presenilin. Nat Cell Biol 7: 1118–1123.
12. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, et al. (2002)
Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297:
240–243.
13. Sampath H, Ntambi JM (2008) Role of stearoyl-CoA desaturase in human
metabolic disease. Future Lipidol 3: 163–173.
14. Corpeleijn E, Feskens EJ, Jansen EH, Mensink M, Saris WH, et al. (2006)
Improvements in glucose tolerance and insulin sensitivity after lifestyle
intervention are related to changes in serum fatty acid profile and desaturase
activities: the SLIM study. Diabetologia 49: 2392–2401.
15. Paillard F, Catheline D, Duff FL, Bouriel M, Deugnier Y, et al. (2008) Plasma
palmitoleic acid, a product of stearoyl-coA desaturase activity, is an independent
marker of triglyceridemia and abdominal adiposity. Nutr Metab Cardiovasc Dis
18: 436–440.
16. Warensjo E, Ingelsson E, Lundmark P, Lannfelt L, Syvanen AC, et al. (2007)
Polymorphisms in the SCD1 gene: associations with body fat distribution and
insulin sensitivity. Obesity (Silver Spring) 15: 1732–1740.
17. Warensjo E, Riserus U, Vessby B (2005) Fatty acid composition of serum lipids
predicts the development of the metabolic syndrome in men. Diabetologia 48:
1999–2005.
18. Mar-Heyming R, Miyazaki M, Weissglas-Volkov D, Kolaitis NA, Sadaat N,
et al. (2008) Association of stearoyl-CoA desaturase 1 activity with familial
combined hyperlipidemia. Arterioscler Thromb Vasc Biol 28: 1193–1199.
19. Windig W, Phalp J, Payne A (1996) A noise and background reduction method
for component detection in liquid chromatography/mass spectrometry. Anal
Chem 68: 3602–3606.
20. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, et al. (2005) A role
for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and
Alzheimer disease. J Clin Invest 115: 2774–2783.
21. Wang J, Yu L, Schmidt R, Su C, Huang X, et al. (2005) Characterization of
HSCD5, a novel human stearoyl-CoA desaturase unique to primates.
Biochemical and biophysical research communications 332: 735–742.
22. Huttunen HJ, Kovacs DM (2008) ACAT as a drug target for Alzheimer’s
disease. Neurodegener Dis 5: 212–214.
23. Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, et al. (2004)
The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a
mouse model of Alzheimer’s disease. Neuron 44: 227–238.
24. Puglielli L, Ellis BC, Ingano LA, Kovacs DM (2004) Role of acyl-coenzyme a:
cholesterol acyltransferase activity in the processing of the amyloid precursor
protein. J Mol Neurosci 24: 93–96.
25. Razay G, Vreugdenhil A, Wilcock G (2007) The metabolic syndrome and
Alzheimer disease. Arch Neurol 64: 93–96.
26. Attie AD, Krauss RM, Gray-Keller MP, Brownlie A, Miyazaki M, et al. (2002)
Relationship between stearoyl-CoA desaturase activity and plasma triglycerides
in human and mouse hypertriglyceridemia. J Lipid Res 43: 1899–1907.
27. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, et al. (2008)
Identification of a lipokine, a lipid hormone linking adipose tissue to systemic
metabolism. Cell 134: 933–944.
28. Uto Y, Ueno Y, Kiyotsuka Y, Miyazawa Y, Kurata H, et al. (2010) Synthesis
and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 19-{6-[5-(pyridin-
3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dih ydrospiro[chromene-
2,49-piperidine] analogs. Eur J Med Chem 45: 4788–4796.
29. Issandou M, Bouillot A, Brusq JM, Forest MC, Grillot D, et al. (2009)
Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin
sensitivity in insulin-resistant rat models. Eur J Pharmacol 618: 28–36.
30. Kalra SP (2008) Central leptin insufficiency syndrome: an interactive etiology for
obesity, metabolic and neural diseases and for designing new therapeutic
interventions. Peptides 29: 127–138.
31. Zhang L, Ge L, Parimoo S, Stenn K, Prouty SM (1999) Human stearoyl-CoA
desaturase: alternative transcripts generated from a single gene by usage of
tandem polyadenylation sites. Biochem J 340(Pt 1): 255–264.
32. Lengi AJ, Corl BA (2008) Comparison of pig, sheep and chicken SCD5
homologs: Evidence for an early gene duplication event. Comp Biochem
Physiol B Biochem Mol Biol 150: 440–446.
33. McNamara RK, Jandacek R, Rider T, Tso P, Stanford KE, et al. (2008) Deficits
in docosahexaenoic acid and associated elevations in the metabolism of
arachidonic acid and saturated fatty acids in the postmortem orbitofrontal
cortex of patients with bipolar disorder. Psychiatry Res 160: 285–299.
34. McNamara RK, Liu Y, Jandacek R, Rider T, Tso P (2008) The aging human
orbitofrontal cortex: decreasing polyunsaturated fatty acid composition and
associated increases in lipogenic gene expression and stearoyl-CoA desaturase
activity. Prostaglandins Leukot Essent Fatty Acids 78: 293–304.
35. Ntambi JM (1999) Regulation of stearoyl-CoA desaturase by polyunsaturated
fatty acids and cholesterol. J Lipid Res 40: 1549–1558.
36. Astarita G, Ahmed F, Piomelli D (2009) Lipidomic analysis of biological samples
by liquid chromatography coupled to mass spectrometry. Methods Mol Biol 579:
201–219.
Stearoyl-CoA Desaturase in Alzheimer’s Disease
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e24777